| Primary |
| Product Used For Unknown Indication |
36.6% |
| Plasma Cell Myeloma |
32.0% |
| Prophylaxis |
8.7% |
| Thrombosis Prophylaxis |
7.2% |
| Pain |
2.7% |
| Infection Prophylaxis |
2.0% |
| Constipation |
1.4% |
| Hypertension |
1.2% |
| Nausea |
1.0% |
| Supplementation Therapy |
1.0% |
| Back Pain |
0.8% |
| Myelofibrosis |
0.8% |
| Anxiety |
0.7% |
| Anaemia |
0.7% |
| Amyloidosis |
0.6% |
| Depression |
0.6% |
| Multiple Myeloma |
0.6% |
| Insomnia |
0.6% |
| Neutropenia |
0.6% |
| Analgesic Therapy |
0.4% |
|
| Plasma Cell Myeloma |
34.3% |
| Death |
10.2% |
| Thrombocytopenia |
9.7% |
| Pneumonia |
6.5% |
| Septic Shock |
6.0% |
| Pancytopenia |
4.6% |
| Pyrexia |
3.2% |
| Renal Failure |
3.2% |
| Renal Failure Acute |
3.2% |
| Sepsis |
2.8% |
| Syncope |
2.3% |
| White Blood Cell Count Decreased |
2.3% |
| Disease Progression |
1.9% |
| Febrile Neutropenia |
1.9% |
| Platelet Count Decreased |
1.9% |
| Lung Infection |
1.4% |
| Unevaluable Event |
1.4% |
| Upper Respiratory Tract Infection |
1.4% |
| Cellulitis |
0.9% |
| Chronic Obstructive Pulmonary Disease |
0.9% |
|
| Secondary |
| Product Used For Unknown Indication |
42.0% |
| Plasma Cell Myeloma |
19.3% |
| Prophylaxis |
10.7% |
| Thrombosis Prophylaxis |
4.9% |
| Multiple Myeloma |
4.6% |
| Pain |
4.1% |
| Infection Prophylaxis |
1.7% |
| Constipation |
1.7% |
| Hypertension |
1.3% |
| Insomnia |
1.3% |
| Anxiety |
1.2% |
| Supplementation Therapy |
1.0% |
| Sleep Disorder |
0.9% |
| Anticoagulant Therapy |
0.8% |
| Back Pain |
0.8% |
| Depression |
0.8% |
| Myelofibrosis |
0.8% |
| Nausea |
0.8% |
| Nasopharyngitis |
0.7% |
| Upper Respiratory Tract Infection |
0.7% |
|
| Plasma Cell Myeloma |
12.1% |
| Pyrexia |
9.6% |
| Thrombocytopenia |
9.6% |
| Colon Cancer |
7.6% |
| Pneumonia |
7.6% |
| Pancytopenia |
7.0% |
| Liver Injury |
6.4% |
| Renal Failure |
5.7% |
| Syncope |
5.1% |
| White Blood Cell Count Decreased |
3.8% |
| Lung Infection |
3.2% |
| Sepsis |
3.2% |
| Urticaria |
3.2% |
| Invasive Ductal Breast Carcinoma |
2.5% |
| Platelet Count Decreased |
2.5% |
| Pulmonary Embolism |
2.5% |
| Septic Shock |
2.5% |
| Fatigue |
1.9% |
| Febrile Neutropenia |
1.9% |
| Interstitial Lung Disease |
1.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
65.4% |
| Insomnia |
7.7% |
| Multiple Myeloma |
7.7% |
| Nausea |
7.7% |
| Agitation |
3.8% |
| Anxiety |
3.8% |
| Vomiting |
3.8% |
|
|
